Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by rtftech16on May 18, 2017 12:39pm
204 Views
Post# 26260131

RE:Seven months...

RE:Seven months...
love_minus_zero wrote: Well here we are, entering into month seven sitting at ten bucks, waiting for management to wisely deploy some of the current three quarters of a billion dollars that's just sitting in the money room.
I remain a believer even though we received a marginal downgrade a few days ago, so perhaps management won't do anything until quests on BNN stop calling management fabulous, and instead question why they raise raise raise but don't deploy? 
lmz


The amount of money I would have lost if I listened to analyst's or banks upgrades downgrades buys holds sells lol. You can't predict what they will do, nor can any analyst or bank. The majority of analyst's are like the majority of realtors: idiots. Yet people listen to their advice for some reason. They are in it for themselves, not for you. Banks can't predict anything from an early stage growth stock. Majority of banks have PT of 10.50-12.50 on this. If GUD was to deploy the majority of its cash tomorrow strategically and got some killer deals the stock would blow past those PT's. Those PT's are basically predicting the 1 year target with current operational income without deploying any of its cash. 
Bullboard Posts